ArticleFrontiers in aging neuroscience2025
AI-driven precision diagnosis and treatment in Parkinson's disease: a comprehensive review and experimental analysis.
Article in Frontiers in aging neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Large language models as a screening tool for the qualification of patients with Parkinson's disease for device-aided therapies.Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
- AI framework for multidisease detection via retinal imaging.Nature medicine · 2026Article
- Current Trends in AI Gait Analysis for the Detection and Assessment of Parkinson's Disease Severity: Systematic Review and Meta-Analysis of Performance Using Logit Transformation.Healthcare (Basel, Switzerland) · 2026Review
- Bio-Inspired Deep Learning for Parkinson's Disease Detection: A Comparative Study Based on Vocal Biomarkers and Archimedean Spiral Analysis.Biomimetics (Basel, Switzerland) · 2026Article
- The future digital outpatient clinic for movement disorders: from technological innovation to ethical and systemic implementation-a position paper.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Artificial intelligence revolutionizing CNS drug discovery and development.Drug discovery today · 2026Review
- A novel multimodal AI framework for early diagnosis of idiopathic Parkinson's disease.Medical & biological engineering & computing · 2026Article
- The Deep Learning Revolution in Neuroimaging: Insights from a Bibliometric Analysis (2014-2024).Neuroinformatics · 2026Review
- AI-Enabled Flexible Sensing Ecosystems for Parkinson's Disease: Advancing Digital Biomarkers and Closed-Loop Interventions.Sensors (Basel, Switzerland) · 2026Review
- Dose-Dependent Neuroprotective Effects of Valproate on Motor Function and Striatal D2 Receptor Stability in a 6-OHDA Rat Model of Parkinson's Disease.International journal of molecular sciences · 2026Article
- Article
- Review
- The gut-brain axis in Alzheimer's and Parkinson's diseases: a comparative perspective.Frontiers in microbiomes · 2026Review
- Long-term outcomes after caudal zona incerta-forel field ablation: three-year clinical follow-up in advanced Parkinson's disease.Frontiers in aging neuroscience · 2026Article
- Artificial Intelligence in Biomedicine: A Systematic Review from Nanomedicine to Neurology and Hepatology.Pharmaceutics · 2025Review
- Editorial: Integrating technology into advanced Parkinson's disease management: from screening and evaluation to treatment and prevention.Frontiers in neurology · 2025Article
- Large language models for neurology: a mini review.Frontiers in digital health · 2025Review
- Multi-modal AI in precision medicine: integrating genomics, imaging, and EHR data for clinical insights.Frontiers in artificial intelligence · 2025Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Parkinson's disease (PD) represents one of the most prevalent neurodegenerative disorders globally, affecting over 10 million individuals worldwide. Traditional diagnostic approaches rely heavily on clinical observation and subjective assessment, often leading to delayed or inaccurate diagnoses. The emergence of artificial intelligence (AI) technologies offers unprecedented opportunities for precision diagnosis and personalized treatment strategies in PD management. Objective: This study aims to comprehensively review current AI applications in Parkinson's disease diagnosis and treatment, evaluate existing methodologies, and present experimental results from a novel multimodal AI diagnostic framework. Methods: A systematic review was conducted across PubMed, IEEE Xplore, and Web of Science databases from 2018 to 2024, focusing on AI applications in PD diagnosis and treatment. Additionally, we developed and tested a hybrid machine learning model combining deep learning, computer vision, and natural language processing techniques for PD assessment using motor symptom analysis, voice pattern recognition, and gait analysis. Results: The systematic review identified 127 relevant studies demonstrating significant advances in AI-driven PD diagnosis, with accuracy rates ranging from 78 to 96%. Our experimental framework achieved 94.2% accuracy in early-stage PD detection, outperforming traditional clinical assessment methods. The integrated approach showed particular strength in identifying subtle motor fluctuations and predicting treatment response patterns. Conclusion: AI-driven approaches demonstrate substantial potential for revolutionizing PD diagnosis and treatment personalization. The integration of multiple data modalities and advanced machine learning algorithms enables earlier detection, more accurate monitoring, and optimized therapeutic interventions. Future research should focus on large-scale clinical validation and implementation frameworks for healthcare systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.